US Patent Issued to Mitsubishi Tanabe Pharma on June 3 for "Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient" (Japanese Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,320,793, issued on June 3, was assigned to Mitsubishi Tanabe Pharma Corp. (Osaka, Japan).

"Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient" was invented by Takeshi Wakasugi (Osaka, Japan) and Aya Sano (Osaka, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining ...